乳腺癌突变型p53与P-gp和GST-π及Topo-Ⅱ表达的相关性研究  

Correlation of mutant p53 with P-gp,GST-π,Topo-Ⅱ in breast cancer

作　　者：孙丽梅[1] 王鲁建[2] 王健[1] 米小轶[1] 

机构地区：[1]中国医科大学基础医学院病理学教研室,辽宁沈阳110001 [2]中国医科大学基础医学院人体解剖学教研室,辽宁沈阳110001

出　　处：《中华肿瘤防治杂志》2013年第17期1323-1326,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨突变型p53蛋白与P-gp、GST-π和Topo-Ⅱ3种耐药蛋白在乳腺癌组织中的表达特点及其临床意义。方法:免疫组化法检测260例乳腺癌中突变型p53与P-gp、Topo-Ⅱ和GST-π的表达情况。结果:乳腺癌中不同组织学类型与P-gp(χ2=3.84,P=0.049)和Topo-Ⅱ(χ2=7.75,P=0.005)表达差异有统计学意义;淋巴结的转移情况与P-gp(χ2=5.09,P=0.024)表达相关;临床分期与突变型p53(χ2=8.48,P=0.036)、P-gp(χ2=6.53,P=0.018)和Topo-Ⅱ(χ2=4.28,P=0.039)表达相关;与预后相关的因素包括突变型p53(χ2=4.26,P=0.039)、P-gp(χ2=19.25,P<0.001)和GST-π(χ2=5.55,P=0.019);突变型p53与P-gp(χ2=5.33,P=0.021)、突变型p53与GST-π(χ2=9.56,P=0.002)和突变型p53与Topo-Ⅱ(χ2=5.23,P=0.022)阳性表达之间均呈显著相关性。结论:突变型p53的表达可能在乳腺癌多药耐药的发生机制中起到了一定的作用。OBJECTIVE： To explain whether expression of mutant p53 gene is correlated to the expressions of P-gp, GST-π and Topo-Ⅱ in breast cancer. METHODS： SP immunohistochemical method was used to examine expressions of mutant p53, P-gp, GST-π and Topo-Ⅱ in 260 samples of primary breast cancer. RESULTS： There were significantly difference between different histological types with P-gp （X2 = 3.84, P = 0. 049） and Topo- Ⅱ （X2 = 7.75, P = 0. 005） ; lymph node metastasis was correlated to P-gp （X2 = 5.09, P= 0. 024） ;clinical stage was correlated to mutant p53 （2 = 8.48, P= 0. 036）,P-gp （X2 =6.53,P=0. 018） and Topo- Ⅱ （X2 =4.28,P=0. 039）;and prognostic factors,including mutant p53 （X2=4.26,P=0.039）,P-gp （2=19.25,P=0.001） and GST-π （X2=5.55,P=0.019）;There were significant correlations between mutant p53 and expressions of P-gp, GST-π and Topo-Ⅱ in breast cancer （X2 = 5.33,P= 0. 021;X2 = 9.56, P=0. 002;7.2= 5.23, P = 0. 022）. CONCLUSION： Expression of mutant p53 may play certain role in the mechanism of multidrug resistance in breast cancer. [

关 键 词：乳腺肿瘤 P53 P-GP GST-Π Topo-Ⅱ 

分 类 号：R737.9[医药卫生—肿瘤]